FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer blockbuster Tasigna lead 2024 patent cliff

Data Compilation
#PharmaFlow

Pipeline Prospector Jan 2025: J&J’s US$ 14.6 bn Intra-Cellular buyout kicks off deal frenzy; Ozempic clinches FDA nod for CKD

Stock Recap
#PipelineProspector

4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

56 API Suppliers, 22 USDMF, 15 CEP/COS, 7 JDMF, 15 EU WC, 27 KDMF, 20 NDC API, 34 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

48 Drugs in Development

48 Drugs in Development

INTERMEDIATES

13 Intermediate Suppliers

13 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

324 FDF Dossiers, 62 FDA Orange Book, 69 Europe, 36 Canada, 34 Australia, 44 South Africa, 79 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG, TABLET;ORAL - 7.5MG, SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 3 Rochem International Inc, 8 SPI Pharma, 11 DKSH, 6 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 7 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pramukh Pharmachem, 4 ACG Worldwide, 7 Actylis, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 20 BASF, 7 DFE Pharma, 7 Gangwal Chemicals, 2 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 26 Kerry, 3 Lonza Capsugel, 12 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Novo Excipients, 5 Pharmatrans-Sanaq, 6 Pluviaendo, 5 Prachin Chemical, 1 Qualicaps, 27 Roquette, 1 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 Ulanqab Kema New Material, 4 Vasa Pharmachem, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

74 Fillers, Diluents & Binders, 41 Disintegrants & Superdisintegrants, 30 Direct Compression, 26 Granulation, 24 Thickeners and Stabilizers, 20 Lubricants & Glidants, 17 Coating Systems & Additives, 16 Taste Masking, 14 Chewable & Orodispersible Aids, 14 Co-Processed Excipients, 12 Controlled & Modified Release, 12 Film Formers & Plasticizers, 10 Solubilizers, 9 Parenteral, 8 Empty Capsules, 7 Topical, 5 Rheology Modifiers, 4 Emulsifying Agents, 3 API Stability Enhancers, 2 Coloring Agents, 1 Surfactant & Foaming Agents, 1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 47 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 57 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

34 APIs, 2 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

79 US Patents, 4 US Exclusivities, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 6 USP, 6 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
24/02/2025	Alkermes Plc	Ireland	ALKERMES INC	18805	MELOXICAM NANOCRYSTAL® TABLETS	2005-09-26	Inactive	II	N/A
24/02/2025	Amsa Spa	Italy	ANONIMA MATERIE SINTETICHE AND AFFINI (AMSA) SPA	17238	MELOXICAM	2004-03-16	Active	II	Complete	2016-04-01	2016-03-02

4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

56 API Suppliers

22 USDMF

15 CEP/COS

7 JDMF

15 EU WC

27 KDMF

20 NDC API

34 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

48 Drugs in Development

INTERMEDIATES

13 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

324 FDF Dossiers

62 FDA Orange Book

69 Europe

36 Canada

34 Australia

44 South Africa

79 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG

TABLET;ORAL - 7.5MG

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem

1 Evonik

3 Rochem International Inc

8 SPI Pharma

11 DKSH

6 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

1 Chynops Pharma

7 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Pramukh Pharmachem

4 ACG Worldwide

7 Actylis

2 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

20 BASF

7 DFE Pharma

7 Gangwal Chemicals

2 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

26 Kerry

3 Lonza Capsugel

12 Microlex e.U

1 Nanjing Bold Chemical

1 NEWEDGE Overseas

2 Novo Excipients

5 Pharmatrans-Sanaq

6 Pluviaendo

5 Prachin Chemical

1 Qualicaps

27 Roquette

1 Seppic

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

2 Ulanqab Kema New Material

4 Vasa Pharmachem

2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

74 Fillers, Diluents & Binders

41 Disintegrants & Superdisintegrants

30 Direct Compression

26 Granulation

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons